Portfolio


Barcode Diagnostics

User-friendly, safe and cost-effective organ removal for laparoscopic surgery

About Us

Ark Surgical is developing and commercializing LapBox, a proprietary simple-to-use device facilitating contained removal of large internal organs through a laparoscopic “keyhole” incision in a safe and cost effective manner. The single-use LapBox employs simple mechanical principles to ensure safe organ removal using a power morcellator without the need for open surgery.

Clinical Need

Efficient laparoscopic surgeries that include the removal of large organs, particularly in gynecology depend on the use of a power morcellator, a device which shreds the large organ, allowing it to be removed from the body via a small incision. Since 2014 there has been a major reduction in the use of power morcellators due to inherent risk of cancerous tissue spreading throughout the surgical cavity.  

Several ad-hoc solutions such as tissue extraction bags are currently in use in order to provide some level of protection when using power morcellators. These solutions, however, are not suited for this purpose and have various challenges when used for organ removal. Laparoscopic organ removal performed today without power morcellation as well as with power morcellation using ad-hoc solutions result in extended procedure times and a higher rate of complications – at a substantial cost to healthcare providers.

In response to FDA’s call for the development of dedicated containment solutions to address this need, new devices are currently being developed by several companies. These solutions, however, appear to be highly complex and time consuming which is expected to limit their market acceptance.  

LapBox

LapBox creates a confined space within the peritoneal cavity that is easily accessible from outside the abdomen. The unique mechanism employed will ensure simple deployment and removal as well as a higher level of safety than provided by other solutions.

Key benefits:

  • User-friendly, rapid set up, operation and removal
  • Improved visibility for the surgeon
  • Enables power morcellation with a high level of safety for the patient

With the LapBox solution, hospitals are expected to benefit from reduced costs through improved workflow efficiency and fewer surgical complications which require additional OR time, prolonged hospitalization and readmissions.  As healthcare providers seek methods to improve overall patient outcomes and quality of care, LapBox is expected to be well received and widely adopted as a standard practice as part of laparoscopic surgery.

Intellectual Property

A US patent has been filed covering the unique concept and structure of the LapBox. 

The Market 

Approximately 500,000 laparoscopic procedures annually that include large organ removal are performed in the US alone with the worldwide number estimated at over 1 million procedures. This offers an estimated market potential for the device of over $500M annually. The key procedures that will be initially targeted for the device include Hysterectomy, Salpingo/Oophorectomy, Ovarian Cystectomy and Myomectomy. Other procedures in Urology will be targeted at a later stage.

The Team

Stav Tori, CEO - Experienced medical device professional with 10 years' experience in developing, manufacturing and clinical testing of medical implants and devices for several biomedical companies such as Carbo-Fix Orthopedics, NMB Medical and Disc-O-Tech.  

Abraham Yaari, Co-founder & Medical Director - Graduated in 1990 from the Hebrew University, Jerusalem, and Specialized in Obstetrics and Gynecology in New York and then practiced in Connecticut. Experienced laparoscopic surgeon. Currently affiliated with Hillel Yaffe Hospital.

Aaron Feldman, Co-founder & Director - Seasoned medical device entrepreneur and manager. Served as CEO of Rafael Medical Technologies and CardioFlow. Currently director of business development of MST – Medical Surgery Technologies and co-founder of Restore Medical (Incentive incubator) and FetalEase Ltd.

Zohar Gendler,  Director  - Managing Partner & CEO of NGT3VC. Former CEO & director of Beta-O2 Technologies (developed proprietary implantable bio-artificial pancreas). Served as CEO of the Technion Technological Incubator for 11 years. Led the establishment and investment in 53 companies, such as Prolor Biotech (sold to OPKO, NYSE: OPK, for $480M), Mazor (NASDAQ: MZOR), ReWalk (NASDAQ: RWLK), Corindus (NASDAQ: CVRS), Regentis, and many others.

 

 


Investors - Contact Us

Entrepreneurs - Contact Us